Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2018; 24(24): 2596-2604
Published online Jun 28, 2018. doi: 10.3748/wjg.v24.i24.2596
Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma
Yang An, Song Gao, Wen-Chao Zhao, Bao-An Qiu, Nian-Xin Xia, Peng-Jun Zhang, Zhen-Ping Fan
Yang An, Wen-Chao Zhao, Bao-An Qiu, Nian-Xin Xia, Department of Hepato-Biliary-Pancreatic Surgey, Navy General Hospital of Chinese People’s Liberation Army, Beijing 100048, China
Song Gao, Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China
Zhen-Ping Fan, The Liver Disease Center for Cadre Medical Care, Beijing 302 Military Hospital, Beijing 100039, China
Author contributions: An Y, Gao S, Zhang PJ and Fan ZP designed the study; An Y, Gao S, Zhao WC, and Xia NX performed the research; An Y, Gao S, Qiu BA, Zhang PJ, and Fan ZP analyzed the date; An Y and Gao S wrote the paper; Zhang PJ and Fan ZP revised the manuscript for final submission; An Y and Gao S contributed equally to this study; Zhang PJ and Fan ZP are the co-corresponding authors.
Supported by the National Key R & D Program of China, No. 2016YFC0106604;and National Natural Science Foundation of China, No. 81502591.
Institutional review board statement: The study was reviewed and approved by the Peking University Cancer Hospital & Institute review board.
Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Zhen-Ping Fan, MD, Doctor, The Liver Disease Center for Cadre Medical Care, Beijing 302 Military Hospital, Xi Si Huan Zhong Road 100, Beijing 100039, China.
Telephone: +86-10-66933466 Fax: +86-10-63879735
Received: March 23, 2018
Peer-review started: March 23, 2018
First decision: April 21, 2018
Revised: April 26, 2018
Accepted: May 6, 2018
Article in press: May 6, 2018
Published online: June 28, 2018
Core Tip

Core tip: We aimed to determine a panel of serum microRNAs (miRNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma (HCC). After TaqMan Low Density Array screening, and validation by RT-qPCR in two phases, we demonstrated that the four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.